Description
This collection of transactions and supporting information was developed using our AI algorithm to curate similar royalty reports into a cohesive collection to support your licensing, transfer pricing or other transaction scenarios where documented royalty rates and/or deal terms are important.
Category: Technology Licenses
Created On: 2022-04-28
Record Count: 4
Primary Industries
- Drugs
- Disease
- Therapeutic
- Pain
IPSCIO Report Record List
Below you will find the records curated into this collection. This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs. The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms. For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report
IPSCIO Record ID: 233443
License Grant
For the exclusive license, Licensor grants to the Licensee of Bermuda an exclusive license, even as to Licensor, in the Territory under Licensor Patent Rights, Licensors and its Controlled Affiliates rights in Joint Patent Rights, and Licensor Know-How, with a right to sublicense, to make, have made, use, offer to sell, sell or import Compound(s) and Product(s) in the Field.
For the Non-Exclusive License Grants Licensor grants to the extent Licensor is legally able to do so, a non-exclusive, sublicensable license in the Territory under any such issued patent for Licensee to make, have made, use, sell, offer for sale or import Compound(s) and Product(s) in the Territory.
And, Licensor grants a non-sublicenseable, non-exclusive license to use Licensor 102,677 for the purpose of developing an assay relating to Licensor 21,947 that quantifies the level, if any, of Licensor 102,677 present in Licensor 21,947 in vitro or in vivo.
License Property
The patents and know-how are for compounds for the treatment and/or prevention of anxiety and/or depression.
Compound shall mean Licensor 21,947, and/or Licensor 216,303. For avoidance of doubt, Compound does not include Licensor 102,677.
Licensor 21,947 shall mean the compound having a chemical name (+)-l-(3,4-dichlorophenyl)-3-azabicyclo[3. l .0]hexane, including all solvates, Prodrugs, salts and polymorphs thereof.
Licensor 102,677 shall mean the compound having a chemical name (-)-l-(3,4-dichlorophenyl)-3-azabicyclo[3. I.0]hexane, including all solvates, Prodrugs, salts and polymorphs thereof.
Licensor 216,303 shall mean the compound having a chemical name (±)-l -(3,4-dichlorophenyl)-3-azabicyclo[3. I.0]hexane, including all solvates, Prodrugs, salts and polymorphs thereof.
Field of Use
The Field shall mean in the case of 21,947, the use of 21 ,947 and/or pharmaceutical preparations in final form containing 21,947 for the treatment and/or prevention and/or diagnosis of diseases and/or medical conditions in humans and/or animals; and in the case of 216,303, the use of 216,303 and/or pharmaceutical preparations in final form containing 216,303 for the treatment and/or prevention and/or diagnosis of depression, anxiety or addiction in humans and/or animals.
IPSCIO Record ID: 233451
License Grant
Licensor grants a worldwide, exclusive license, with the right to sublicense, under the Licensors Rights, to Develop, make, have made, use, sell, offer for sale, have sold and import the Compound and Products in the Field, and otherwise to perform its obligations expressly set forth in this Agreement and the Co-Promotion Agreement.
License Property
The Compound means either (a) the Initial Compound or (b) any compound that is claimed in U.S. Patent No. 6,288,122 Bl and any hydrates, anhydrides, solvates, salts, esters or polymorphs thereof.
The initial compound means the compound ICA-17043 having the molecular structure set forth and any hydrates, anhydrides, solvates, salts, esters, isomers, prodrugs, metabolites or polymorphs thereof.
The Product means a pharmaceutical product that contains, incorporates or is comprised of the Compound, whether in development or approved by any Regulatory Authority, including all formulations, line extensions and modes of administration thereof.
The Licensor Patents means all Patents, other than CMCC Patents, Controlled by Licensor as of the Effective Date or during the Term, that, absent rights thereunder, would be infringed by the Development, Manufacture, formulation, use, distribution, importation, sale, or offer for sale of Compound or Product, including without limitation any such Patents claiming the composition of matter or the use of Compound or Product or any Improvements thereto.
Licensors know-how means all Information, except for CMCC Know-How, that Licensor Controls as of the Effective Date or during the Term.
Field of Use
The field means prevention and treatment of all human and animal diseases and disorders. The licensed technology is for use of these compounds include treating sickle cell disease, preventing erythrocyte dehydration and inhibiting potassium flux.
IPSCIO Record ID: 249736
License Grant
For the Exclusive License. Licensor grants a non-transferable, sole and exclusive, even as to Licensor and its Affiliates, worldwide license, with the right to sublicense, under the Licensor Patent Rights and Know-How, to make, have made, use, sell, offer to sell, import, research, develop, commercialize and otherwise exploit the Licensed Compound and Licensed Product in the Field in the Territory.
License Property
The Licensed Compound means Bicifadine and any prodrugs, optical isomers, hydrates, solvates, salt forms and polymorphs of Bicifadine.
Bicifadine (DOV-220075) is a nonopioid analgesic. It is an inhibitor of both the norepinephrine and serotonin transporters and an NMDA antagonist with a non-narcotic profile. Bicifadine was shown to have potent analgesic activity in vivo and was chosen for further development for the treatment of pain.
Field of Use
Field means the treatment of any diseases, disorders and conditions in humans, other than the treatment or amelioration of vasomotor symptoms caused by or occurring in relation to or connection with menopause or other female hormonal fluctuations in a patient undergoing treatment.
IPSCIO Record ID: 239024
License Grant
The Licensor of Spain grants to an exclusive, even as to Licensor, license under the Patent Assets and the Licensor Know-How, including the right to grant sublicenses, to develop, make, have made, use, import, offer for sale, promote, market, commercialize, distribute and sell Product in the Territory, and insofar as necessary for the purposes of exercising such rights, to develop, make, have made, use, import, offer for sale, commercialize, distribute and sell Compound.
License Property
The compound is UR-12746 Sodium Salt, meaning UR-12746 (including UR-12715) and UR-12746(S), and any derivative, homolog or analog of any of the foregoing or any isomer, salt, hydrate, solvate, amide, ester, metabolite, or prodrug of any of the foregoing, and any pharmaceutical composition containing any of the foregoing in any pharmaceutically acceptable form.
Licensor possesses significant expertise in the field of antiinflammatory therapeutics, and dersalazine represents the culmination of years of internal research.
Dersalazine is a new chemical entity that combines a well-known anti-inflammatory agent, 5-ASA, with a novel potent agent that acts as a PAF antagonist and an inhibitor of key interleukin cytokines to achieve a synergistic therapeutic effect when compared to the activities of each component separately. Chemical cleavage of dersalazine by colonic bacteria releases the two active compounds for the topical treatment of inflammation in the colon. The 5-ASA molecule contained in dersalazine has known antioxidant properties which may ameliorate the deleterious inflammatory effects ascribed to the overproduction of free radicals.
Field of Use
Dersalazine is a compound in early clinical development to treat Inflammatory Bowel Disease (IBD), which includes ulcerative colitis and Crohn's disease.
Disclaimer: The information gathered from RoyaltySource® database was sourced from the U.S. Securities and Exchange Commission EDGAR Filings and other public records. While we believe the sources to be reliable, this does not guarantee the accuracy or completeness of the information provided. Further, the information is supplied as general guidance and is not intended to represent or be a substitute for a detailed analysis or professional judgment. This information is for private use only and may not be resold or reproduced without permission.
